A new report from IMARC Group expects a strong uptake of DPP-IV Inhibitors and other new drug classes to drive sales in the Turkish Oral Antidiabetics market during 2011-2016
By : |
10-01-2011
|
Health and Fitness:Health and Fitness
| Total Views :
553